Nasdaq's Biotech Competitors
Executive Summary
Unless Europe can create viable public markets for companies likely to lose money for years, the European biotech industry will be dead before it gets to solve any of its other major problems (like finding capable managers or getting the buy-in of its best academics). So far most of the IPOs have not taken place where most of the start-ups are located--Germany. Still, the European markets do offer an intriguing alternative for US companies shut out of the US stock market.